Corrigendum to ‘Cardiovascular adverse events are associated with usage of immune checkpoint inhibitors in real-world clinical data across the United States’: [ESMO Open Volume 6, Issue 5, October 2021, 100252]

Corrigendum to ‘Cardiovascular adverse events are associated with usage of immune checkpoint inhibitors in real-world clinical data across the United States’: [ESMO Open Volume 6, Issue 5, October 2021, 100252]

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:ESMO open 2021-12, Vol.6 (6), p.100286-100286, Article 100286
Hauptverfasser: Jain, P., Gutierrez Bugarin, J., Guha, A., Jain, C., Patil, N., Shen, T., Stanevich, I., Nikore, V., Margolin, K., Ernstoff, M., Velcheti, V., Barnholtz-Sloan, J., Dowlati, A.
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:
ISSN:2059-7029
2059-7029
DOI:10.1016/j.esmoop.2021.100286